Effectiveness of LORlatinib as a Real-World, first-line treatment in ALK-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients in Italy(LOR-ALK).

10/06/2026
10/06/2026
EU PAS number:
EUPAS1000000856
Study
Planned
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

B7461061_NIS PASS Study Protocol_Completed Review NISRC-O_V1.1_19May2026 (1)_Redacted.pdf

English (3.98 MB - PDF) View document
Study results
Study report
Other information